The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema

@inproceedings{Eaton2018TheUS,
  title={The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema},
  author={Alexander Eaton and Sean S. Koh and Jaime R. Pag{\'a}n Jim{\'e}nez and Christopher D. Riemann},
  booktitle={Ophthalmology and Therapy},
  year={2018}
}
IntroductionTo determine anatomical, functional, and intraocular pressure (IOP) responses to diabetic macular edema (DME) treatments pre- and post-0.2 µg/day fluocinolone acetonide (FAc) implant administration compared with baseline and the preceding 3 years.MethodsThis was a retrospective, chart review, cohort study in four U.S. centers. Patients received the 0.2 µg/day FAc implant for the treatment of DME in at least one eye before January 1, 2016. DME treatments administered up to 36 months… CONTINUE READING
3
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits.

  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2015

Diabetic Macular Edema: Current and Emerging Therapies

  • Middle East African journal of ophthalmology
  • 2012
VIEW 1 EXCERPT